Compare MCB & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | TNDM |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2017 | 2013 |
| Metric | MCB | TNDM |
|---|---|---|
| Price | $98.48 | $16.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $98.67 | $28.00 |
| AVG Volume (30 Days) | 137.7K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 2.92 | N/A |
| Revenue | $11,053,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $37.22 | $8.11 |
| Revenue Next Year | $14.75 | $11.85 |
| P/E Ratio | $34.60 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $64.66 | $10.00 |
| 52 Week High | $102.04 | $29.65 |
| Indicator | MCB | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 57.06 |
| Support Level | $86.38 | $13.59 |
| Resistance Level | $102.04 | $20.79 |
| Average True Range (ATR) | 2.49 | 0.91 |
| MACD | -0.16 | 0.19 |
| Stochastic Oscillator | 49.34 | 98.76 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.